{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T14:22:10Z","timestamp":1782656530243,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>There is concern that the coronavirus disease (COVID-19) vaccine may trigger or worsen autoimmune diseases. The objective of this study was to determine the impacts of COVID-19 vaccination on symptom severity in patients with myasthenia gravis (MG).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 106 enrolled patients with MG who were vaccinated against COVID-19 were followed up, and a questionnaire was used to document in detail the exacerbation of muscle weakness after vaccination and all other uncomfortable reactions after vaccination. Demographic, clinical characteristics, medication, and vaccination data were collected by follow-up interview. The main observation outcome was whether the MG symptoms of patients were exacerbated. The definition of exacerbation is according to the subjective feeling of the patient or a 2-point increase in daily life myasthenia gravis activity score relative to before vaccination, within 30 days after vaccination.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 106 enrolled patients [median age (SD) 41.0 years, 38 (35.8%) men, 53 (50.0%) with generalized MG, 74 (69.8%) positive for acetylcholine receptor antibody, and 21 (19.8%) with accompanying thymoma], muscle weakness symptoms were stable in 102 (96.2%) patients before vaccine inoculation. Muscle weakness worsened in 10 (9.4%) people after vaccination, of which 8 patients reported slight symptom worsening that resolved quickly (within a few days). Two (1.9%) of patients showed serious symptom aggravation that required hospitalization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results suggest that inactivated virus vaccines against COVID-19 may be safe for patients with MG whose condition is stable. Patients with generalized MG may be more likely to develop increased muscle weakness after vaccination.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10072-023-06811-y","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T23:26:33Z","timestamp":1683761193000},"page":"2239-2245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An observational study on the safety of COVID-19 vaccination in patients with myasthenia gravis"],"prefix":"10.1007","volume":"44","author":[{"given":"H.Y.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.Y.","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.Q.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.D.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.R.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1909-4898","authenticated-orcid":false,"given":"W.B.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"issue":"10","key":"6811_CR1","doi-asserted-by":"publisher","first-page":"985","DOI":"10.4103\/0301-4738.145987","volume":"62","author":"AG Nair","year":"2014","unstructured":"Nair AG, Patil-Chhablani P, Venkatramani DV et al (2014) Ocular myasthenia gravis: a review. Indian J Ophthalmol 62(10):985\u2013991","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"6811_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","volume":"36","author":"MK Hehir","year":"2018","unstructured":"Hehir MK, Silvestri NJ (2018) Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology. Neurol Clin 36(2):253\u2013260","journal-title":"Neurol Clin"},{"issue":"5","key":"6811_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/WCO.0000000000000473","volume":"30","author":"A Evoli","year":"2017","unstructured":"Evoli A (2017) Myasthenia gravis: new developments in research and treatment. Curr Opin Neurol 30(5):464\u2013470","journal-title":"Curr Opin Neurol"},{"key":"6811_CR4","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3389\/fneur.2020.01053","volume":"11","author":"AE Camelo-Filho","year":"2020","unstructured":"Camelo-Filho AE, Silva A, Estephan EP et al (2020) Myasthenia gravis and COVID-19: clinical characteristics and outcomes. Front Neurol 11:1053","journal-title":"Front Neurol"},{"issue":"12","key":"6811_CR5","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S1474-4422(20)30413-0","volume":"19","author":"S Muppidi","year":"2020","unstructured":"Muppidi S, Guptill JT, Jacob S et al (2020) COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurol 19(12):970\u2013971","journal-title":"Lancet Neurol"},{"issue":"10","key":"6811_CR6","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2020.15543","volume":"324","author":"S Xia","year":"2020","unstructured":"Xia S, Duan K, Zhang Y et al (2020) Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA 324(10):951\u2013960","journal-title":"JAMA"},{"issue":"10","key":"6811_CR7","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1111\/ene.14951","volume":"28","author":"M Jakubikova","year":"2021","unstructured":"Jakubikova M, Tyblova M, Tesar A et al (2021) Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol 28(10):3418\u20133425","journal-title":"Eur J Neurol"},{"key":"6811_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1475-2859-5-23","volume":"5","author":"A Detmer","year":"2006","unstructured":"Detmer A, Glenting J (2006) Live bacterial vaccines--a review and identification of potential hazards. Microb Cell Fact 5:23","journal-title":"Microb Cell Fact"},{"issue":"3","key":"6811_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s13167-017-0101-y","volume":"8","author":"M Vadala","year":"2017","unstructured":"Vadala M, Poddighe D, Laurino C et al (2017) Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? EPMA J 8(3):295\u2013311","journal-title":"EPMA J"},{"issue":"7","key":"6811_CR10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.vaccine.2019.01.007","volume":"37","author":"E Strijbos","year":"2019","unstructured":"Strijbos E, Tannemaat MR, Alleman I et al (2019) A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis. Vaccine 37(7):919\u2013925","journal-title":"Vaccine"},{"issue":"4","key":"6811_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3988\/jcn.2017.13.4.325","volume":"13","author":"HY Seok","year":"2017","unstructured":"Seok HY, Shin HY, Kim JK et al (2017) The impacts of influenza infection and vaccination on exacerbation of myasthenia gravis. J Clin Neurol 13(4):325\u2013330","journal-title":"J Clin Neurol"},{"issue":"5","key":"6811_CR12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/annrheumdis-2012-201393","volume":"72","author":"CC Mok","year":"2013","unstructured":"Mok CC, Ho LY, Fong LS et al (2013) Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 72(5):659\u2013664","journal-title":"Ann Rheum Dis"},{"key":"6811_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jneuroim.2021.577599","volume":"356","author":"H Kelly","year":"2021","unstructured":"Kelly H, Sokola B, Abboud H (2021) Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. J Neuroimmunol 356:577\u2013599","journal-title":"J Neuroimmunol"},{"issue":"16","key":"6811_CR14","doi-asserted-by":"publisher","first-page":"e2109","DOI":"10.1212\/WNL.0000000000011669","volume":"96","author":"G Sole","year":"2021","unstructured":"Sole G, Mathis S, Friedman D et al (2021) Impact of coronavirus disease 2019 in a French cohort of myasthenia gravis. Neurology 96(16):e2109\u2013e2120","journal-title":"Neurology"},{"issue":"10","key":"6811_CR15","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3390\/vaccines9101112","volume":"9","author":"Z Ruan","year":"2021","unstructured":"Ruan Z, Tang Y, Li C et al (2021) COVID-19 vaccination in patients with myasthenia gravis: a single-center case series. Vaccines 9(10):1112","journal-title":"Vaccines"},{"issue":"6","key":"6811_CR16","first-page":"e15581","volume":"13","author":"AR Tagliaferri","year":"2021","unstructured":"Tagliaferri AR, Narvaneni S, Azzam MH et al (2021) A case of COVID-19 vaccine causing a myasthenia gravis crisis. Cureus 13(6):e15581","journal-title":"Cureus"},{"issue":"46","key":"6811_CR17","doi-asserted-by":"publisher","first-page":"6290","DOI":"10.1016\/j.vaccine.2017.09.078","volume":"35","author":"E Strijbos","year":"2017","unstructured":"Strijbos E, Huijbers MG, van Es IE et al (2017) A prospective, placebo controlled study on the humoral immune response to and safety of tetanus revaccination in myasthenia gravis. Vaccine 35(46):6290\u20136296","journal-title":"Vaccine"},{"issue":"10229","key":"6811_CR18","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, Mcauley DF, Brown M et al (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395(10229):1033\u20131034","journal-title":"Lancet"},{"key":"6811_CR19","first-page":"143","volume":"28","author":"B Tackenberg","year":"2018","unstructured":"Tackenberg B, Schneider M, Blaes F et al (2018) acetylcholine receptor antibody titers and clinical course after influenza vaccination in patients with myasthenia gravis: a double-blind randomized controlled trial (ProPATIent-Trial). E BioMed 28:143\u2013150","journal-title":"E BioMed"},{"issue":"6","key":"6811_CR20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3899\/jrheum.170710","volume":"45","author":"S Subesinghe","year":"2018","unstructured":"Subesinghe S, Bechman K, Rutherford AI et al (2018) A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis. J Rheumatol 45(6):733\u2013744","journal-title":"J Rheumatol"},{"issue":"7","key":"6811_CR21","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/acr.22246","volume":"66","author":"C Hua","year":"2014","unstructured":"Hua C, Barnetche T, Combe B et al (2014) Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 66(7):1016\u20131026","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06811-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-06811-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06811-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T04:07:18Z","timestamp":1686370038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-06811-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["6811"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-06811-y","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"assertion":[{"value":"5 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Medical Ethics Committee for Clinical Research and Animal Trials of the First Affiliated Hospital of Sun Yat-sen University (Application ID:[2022]113).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All study participants provided informed consent, and the study design was approved by the appropriate ethics review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}